Fecal Microbiota Transplantation

CHICAGO — Fecal microbiota transplantation that contains effective microbiota may overcome resistance to anti-PD-1 therapy among patients with advanced solid cancers, according to data presented at ASCO Annual Meeting.

CHICAGO — In a Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, discusses data showing consistent safety and efficacy of Rebyota when administered via colonoscopy for prevention of recurrent Clostridioides difficile infection.

CHICAGO — In a Healio video exclusive, Glenn S. Tillotson, MSc, PhD, discusses the safety and sustained efficacy of Rebyota at 6 months for recurrent Clostridioides difficile infection in patients with immunocompromising conditions.

A hospital that replaced sink drains and traps in an ICU, hoping to curtail an outbreak of Klebsiella pneumoniae carbapenemase-producing bacteria, instead saw patients infected in a new outbreak of Serratia marcescens, according to a study.

A novel oral microbiome-directed therapy called VE303 successfully prevented recurrent Clostridioides difficile infection in adults at high risk for recurrence, researchers found.

A recent review of randomized controlled trials — most of which were conducted before the COVID-19 pandemic — has become part of the debate on the effectiveness of masks in preventing the spread of respiratory illnesses.

Bezlotoxumab and fecal microbiota transplantation were similarly effective at preventing both early and late recurrent Clostridioides difficile infection, according to a study published in Open Forum Infectious Diseases.

There were several important FDA approvals for GI conditions over the past year, including the first treatment for eosinophilic esophagitis and the first approved fecal microbiota therapeutic.

Fecal microbiota transplantation 6 months before bariatric surgery did not reduce body weight in a small cohort of patients with obesity in Finland, according to study results published in JAMA Network Open.

The FDA recently cleared the endoscopic hemostasis system Nexpowder, which is intended to improve visibility and management of nonvariceal upper gastrointestinal bleeding, according to the manufacturer Medtronic.